How genomic data is guiding colorectal cancer treatment

Colorectal cancer is increasingly treated according to the biology of an individual tumour, rather than its location and stage alone. Genomic testing can reveal DNA changes that help clinicians select medicines, estimate likely treatment response and identify patients who may benefit from a clinical trial.

This approach covers several forms of information. Tumour profiling examines mutations and molecular features in cancer cells, while germline testing looks for inherited variants that may affect a person and their relatives. Blood-based tests can also detect circulating tumour DNA, offering a way to monitor residual disease after surgery or identify relapse earlier.

For patients in Australia, the value of genomic medicine depends on more than laboratory technology. Results must be available quickly, interpreted by a multidisciplinary team and connected with affordable treatment, genetic counselling and appropriate follow-up. This is where research translation partnerships can help move evidence into everyday care, as demonstrated by Brisbane Diamantina Health Partners.

The need is significant across metropolitan, regional and remote communities. People treated in Brisbane, regional Queensland or elsewhere in Australia may face different access to specialist pathology, trials and genetic services. A coordinated system can help ensure that a postcode does not determine whether useful genomic information changes a treatment plan.

Reading the molecular profile of a tumour

A colorectal tumour may contain several alterations that influence its behaviour. Testing commonly includes the RAS genes, especially KRAS and NRAS, because mutations in these genes can predict whether anti-EGFR medicines such as cetuximab or panitumumab are unlikely to work. BRAF V600E status is also clinically important, as it may support a targeted combination for advanced disease.

Other biomarkers can open different treatment pathways. Deficient mismatch repair and microsatellite instability-high status indicate a problem with the system that corrects DNA copying errors. In some advanced cancers, these features are associated with a strong response to immune checkpoint inhibitors. HER2 amplification, NTRK fusions and selected KRAS G12C mutations may also identify patients for targeted therapies, although eligibility depends on the full clinical picture and approved indications in Australia.

Matching treatment to risk and response

Genomic results are most useful when combined with stage, imaging, pathology, symptoms and a person’s overall health. A mutation does not automatically mean that a particular drug is suitable. Oncologists consider the strength of the evidence, previous therapies, side effects, drug access and whether a treatment is listed through Australia’s Pharmaceutical Benefits Scheme or available through a trial.

The same principle applies after surgery. Circulating tumour DNA, sometimes called a liquid biopsy, can detect small amounts of cancer-related DNA in the bloodstream. A positive result may suggest a higher risk of recurrence and help identify people who need closer monitoring or additional treatment. This technology is still being evaluated for many decisions, so it should support—not replace—careful clinical judgement and shared decision-making.

Using inherited information responsibly

Some colorectal cancers are linked to inherited conditions such as Lynch syndrome or familial adenomatous polyposis. A tumour showing mismatch repair deficiency can prompt further testing to distinguish an acquired change from an inherited one. If a hereditary risk is confirmed, relatives may be offered genetic counselling and appropriate surveillance, potentially detecting bowel cancer earlier or preventing it through removal of high-risk polyps.

Consent, privacy and communication are central to this process. Patients need to understand what a test may reveal about their own health, family members and future care. Genetic services must also be culturally safe and accessible, including for Aboriginal and Torres Strait Islander peoples and families who may live far from major hospitals. Experience from mobile screening programs shows how outreach and trusted community connections can strengthen participation in health programs; similar principles matter for genomic care.

Making genomic medicine work across Australia

A genomic result has practical value only when it can travel from the laboratory report to the treating team. This requires validated tests, consistent reporting, secure health information systems and clear referral pathways. In Queensland, collaboration between hospitals, universities, research institutes and health services can support this flow, particularly for patients moving between a local hospital and a tertiary centre such as those in Brisbane.

Geography and workforce capacity remain important. A patient in Cairns, Mount Isa or a remote Queensland community may need telehealth genetic counselling, coordinated sample transport and help accessing a specialist review. Australia’s public health system, Medicare arrangements and state-based services can make pathways complex, while medicine funding and trial eligibility may change over time. Strong governance helps clinicians explain these limits honestly and avoid promising a treatment solely because a molecular alteration has been found.

Turning research findings into better care

Genomic databases become more powerful when clinical outcomes are linked with molecular information in a secure, ethically governed way. Researchers can learn which variants are meaningful, which patients benefit from immunotherapy and why resistance develops. Patients may then gain access to trials testing new combinations, vaccines or targeted medicines before those approaches become standard practice.

Translation also requires partnerships with industry, consumers and health services. Developing a diagnostic test or digital tool involves validation, regulation, reimbursement and implementation, not just an interesting research result. Guidance on bringing medical devices to market reflects the broader work needed to turn innovation into something clinicians can use safely and consistently.

For people living with colorectal cancer, genomic information should lead to a clearer care pathway: an understandable explanation of the result, a treatment plan grounded in evidence, and follow-up that responds to changing risk. Families should know when hereditary testing is relevant, and clinicians should have access to timely advice when results are uncertain.

Researchers, health services and community partners can help accelerate this progress by sharing data responsibly, supporting inclusive clinical trials and evaluating genomic tests in real Australian settings. Patients and carers can contribute through informed consent, consumer advisory groups and research participation, helping shape a cancer system where precision treatment is clinically useful, equitable and connected to everyday care.